StageUnattributed VC - II | Alive
Last Raised$18.5M | 23 yrs ago
About Cardiodynamics International Corporation
CardioDynamics was incorporated in 1993 and is committed to fundamentally changing drug management with ICG. The Company's primary product, the BioZ, uses proprietary Impedance Cardiography (ICG) technology to noninvasively assess a patient's hemodynamics, data which typically has been unavailable in the physician's office and available on a limited basis in the hospital only through a time-consuming, costly, and potentially dangerous invasive procedure called Pulmonary Artery Catheterization (PAC), or the Swan Ganz Catheter. Since the BioZ's ICG monitoring is noninvasive, it can be performed in outpatient areas such as physician offices, which have never before had access to hemodynamic information in treating heart failure, high blood pressure, pacemaker, and dialysis patients. In physician offices, BioZ monitoring can decrease long term costs of hypertension management through the use of appropriate drug therapies. The reduction of blood pressure results in a decrease of more costly cardiovascular conditions including heart failure, strokes, and heart attacks. In hospitals, BioZ monitoring on surgical or intensive care patients can decrease costs through the elimination of procedure risk, reduction of hospital stay, and minimization of hospital expenditures and personnel. BioZ monitoring can also provide valuable hemodynamic information in hospital areas where previously it has not been available, such as emergency departments, critical care, step-down units, and dialysis. In this new era of cost containment, healthcare payors and providers are demanding greater efficiency and cost-effectiveness without diminishing the quality of care. The BioZ's ICG monitoring systems provide a solution to meet this growing demand.
Missing: Cardiodynamics International Corporation's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Cardiodynamics International Corporation's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Cardiodynamics International Corporation Patents
Cardiodynamics International Corporation has filed 2 patents.
Molecular biology, Biotechnology, Biomaterials, Cardiac procedures, Genomics
Molecular biology, Biotechnology, Biomaterials, Cardiac procedures, Genomics
Latest Cardiodynamics International Corporation News
Mar 15, 2022
Neuro Critical Care Market Is Set To Garner Staggering Revenues By 2031 Fact.MR has prepared and presented a research report on the Global Neuro Critical Care Market and has made optimum utilization of various multi-disciplinary approaches to arrive at the estimates and conclusions that have been shared in the report. The Global Neuro Critical Care Market has been prepared for a period of forecast that extends from 2021 to 2028. Offering an in-depth analysis of the major opportunities of growth and key prospects in the estimation year, the report has been drawn up a team of seasoned analysts who have meticulously assessed all the factors pertaining to the market. The report also explains vividly the prevailing dynamics of growth in the market over the assessment period, 2021 to 2028. At the same time, the study prepares the stakeholders for dealing with the threats and challenges related to the global Neuro Critical Care market effectively and efficiently. The experience and knowledge of the researchers and analysts have been leveraged in authoring this report so as to offer a detailed report. Authors have meticulously considered the prevailing pandemic, SARS-CoV-2 induced Covid-19, and have taken the implications of the outbreak into consideration to arrive at the estimations and conclusions. Analysts at Fact.MR has made a careful analysis of the market in pre- and present Covid-19 times to derive estimations and projections for the Global Neuro Critical Care Market in the post-pandemic era. Get Request for PDF Brochure of This Market Research Report https://www.factmr.com/connectus/sample?flag=B&rep_id=2284 Multiple rounds of primary and exhaustive secondary research have been conducted and the data thus gathered have been utilized to analyze by the professionals at Fact.MR to come up with accurate estimations and projections for the Global Neuro Critical Care Market. In an effort to provide the users of this report with a comprehensive view of the Global Neuro Critical Care Market, experts have included an elaborate discussion on the competitive scenario and product portfolio of each of the key vendors spread across various geographies. The report study also makes inclusion of SWOT analysis and PESTEL analysis of the said industry. The study incorporates a market attractiveness analysis, in which all of the segments have been benchmarked based on their growth rate, market size, and general attractiveness in terms of incremental value growth and investment opportunity. To understand of the competitive landscape in the Global Neuro Critical Care Market better, the report covers the profile of the following top players: Abbott, Teleflex Incorporated, Aspect Medical Systems, Inc., CardioDynamics International Corporation, Medtronic, General Electric Company, Edwards Lifesciences Corporation, Integra LifeSciences Corporation., Philips N.V., Drägerwerk AG & Co. KGaA, and Terumo Medical Corporation, among others. Global Neuro Critical Care Market Segmentation Based on equipment type, the global neuro critical care market is segmented as: Diagnostics Subarachnoid Hemorrhage Neuromuscular Disorders Hospitals After going through the study on Global Neuro Critical Care Market, readers will get valuable insight into the following: The challenges, restraints, opportunities, and drivers prevailing in the Global Neuro Critical Care Market New as well as promising major avenues of growth in key geographies of the market Emerging revenue streams for all the market players in the developing regions The competitive landscape with profiles of leading market players Technologies and business models with disruptive potential Influence of Covid-19 in the market and how the pandemic is going to shape the contours of the market in the forthcoming years Another key feature of this report is the analysis of the global Neuro Critical Care market and the corresponding revenue forecast in terms of absolute dollar opportunity. This is usually overlooked while forecasting the market. However, absolute dollar opportunity is critical in assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales perspective in the global Neuro Critical Care market. The report covers an in-depth analysis of all components of the value chain in the global Neuro Critical Care market. In the final section of the report on the global Neuro Critical Care market, a competitive landscape is included to provide a dashboard view of global Neuro Critical Care manufacturers. Decisive Information Enclosed in the report: The scenario of the global Neuro Critical Care market in different regions Current market trends influencing the growth of the Neuro Critical Care market Factors expected to hinder the growth of the global Neuro Critical Care market Micro and macro-economic factors shaping the growth of the market in different regions Key strategies adopted by players to gain a competitive edge in the Neuro Critical Care market. For More Insights- https://www.globenewswire.com/news-release/2022/03/09/2400432/0/en/Low-Code-Development-Industry-is-Projected-to-Achieve-a-Global-Market-Size-of-US-187-Bn-by-2032-Currently-US-Accounts-For-the-Largest-Market-Share-in-the-World.html About Us: Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analysed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner. Contact:
Cardiodynamics International Corporation Frequently Asked Questions (FAQ)
When was Cardiodynamics International Corporation founded?
Cardiodynamics International Corporation was founded in 1980.
Where is Cardiodynamics International Corporation's headquarters?
Cardiodynamics International Corporation's headquarters is located at 6175 Nancy Ridge Drive, San Diego.
What is Cardiodynamics International Corporation's latest funding round?
Cardiodynamics International Corporation's latest funding round is Unattributed VC - II.
How much did Cardiodynamics International Corporation raise?
Cardiodynamics International Corporation raised a total of $23.5M.
Who are the investors of Cardiodynamics International Corporation?
Investors of Cardiodynamics International Corporation include CDP Capital and Domain Associates.
Who are Cardiodynamics International Corporation's competitors?
Competitors of Cardiodynamics International Corporation include Saladax Biomedical, Third Eye Diagnostics, MSDx, Crescendo Bioscience, MEC Dynamics and 14 more.
Compare Cardiodynamics International Corporation to Competitors
MSDx is engaged in an effort to improve the diagnosis of Multiple Sclerosis by offering the first definitive, simple, fast, and cost effective blood test for health care professionals and patients around the world.
Tensys Medical Tensys has developed a continuous, non-invasive blood pressure monitoring technology for cardiac output assessment that is easy to administer and comfortable for the patient. San Diego, CA.
XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. Per the company, they have developed a proprietary method of utilizing gene expression in blood that aims to provide a new tool for physicians to manage the care of heart transplant patients. The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.
Daktari Diagnostics develops products that deliver critical diagnostic information to clinicians and patients. Daktari's initial product is a handheld CD4 cell counter that aims to enable CD4 counting to be done by anyone. The company intends to bring this blood test to parts of the world where millions of people now have access to life-saving drugs, yet cannot begin treatment due to inadequate diagnostics.
Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.
NeuroDx addresses important unmet needs in the neurosurgical market. Their lead product, ShuntCheck, is an aid to the detection offlow in implanted cerebrospinal fluid (CSF) shunts.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.